JAK-IN-5

Cat. No.: HY-111471: Data Sheet Handling Instructions
FAQs
Technical Support

JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (JAK-IN-5 hydrochloride) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

JAK-IN-5 Chemical Structure

CAS No. : 2096999-92-5

Size	Price	Stock
5 mg		Ask For Quote & Lead Time
10 mg		Ask For Quote & Lead Time
25 mg		Ask For Quote & Lead Time
50 mg		Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of JAK-IN-5:

JAK-IN-5 hydrochloride

Other Forms of JAK-IN-5:

JAK-IN-5 hydrochloride In-stock

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All JAK Isoform Specific Products:

View All Isoforms

JAK1 JAK2 JAK3 Tyk2 JAK

Biological Activity
Purity & Documentation
References
Customer Review

Description

JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.

IC₅₀ & Target

JAK^[1]

In Vivo

JAK-IN-5 (compound 1) (oral aspirate, 0.5 mg/mL, 50 μL ) inhibits STAT6 phosphorylation by 60% in IL-13-induced in lung tissue in a mouse model of pSTAT6 induction^[2].
JAK-IN-5 (compound 1) (oral aspirate, 0.1-1.0 mg/mL, 50 μL) inhibits 88% of BALF eosinophils in male C57 mice model of Alternaria alternata-induced eosinophilic inflammation of the lung^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

474.57

Formula

C₂₇H₃₁FN₆O

CAS No.

2096999-92-5

SMILES

CN1CCC(N2CC(N=C(C3=NNC4=C3C=CC(C5=C(CC)C=C(O)C(F)=C5)=C4)N6)=C6CC2)CC1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (210.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1072 mL	10.5359 mL	21.0717 mL
5 mM	0.4214 mL	2.1072 mL	4.2143 mL
10 mM	0.2107 mL	1.0536 mL	2.1072 mL

View the Complete Stock Solution Preparation Table

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Paul R. Fatheree, et al. JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease. US20170121327A1

[2]. Venkat R, et al. Methods of treatment using a jak inhibitor compound. US20180311226.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1072 mL	10.5359 mL	21.0717 mL	52.6793 mL
	5 mM	0.4214 mL	2.1072 mL	4.2143 mL	10.5359 mL
	10 mM	0.2107 mL	1.0536 mL	2.1072 mL	5.2679 mL
	15 mM	0.1405 mL	0.7024 mL	1.4048 mL	3.5120 mL
	20 mM	0.1054 mL	0.5268 mL	1.0536 mL	2.6340 mL
	25 mM	0.0843 mL	0.4214 mL	0.8429 mL	2.1072 mL
	30 mM	0.0702 mL	0.3512 mL	0.7024 mL	1.7560 mL
	40 mM	0.0527 mL	0.2634 mL	0.5268 mL	1.3170 mL
	50 mM	0.0421 mL	0.2107 mL	0.4214 mL	1.0536 mL
	60 mM	0.0351 mL	0.1756 mL	0.3512 mL	0.8780 mL
	80 mM	0.0263 mL	0.1317 mL	0.2634 mL	0.6585 mL
	100 mM	0.0211 mL	0.1054 mL	0.2107 mL	0.5268 mL

JAK-IN-5 Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

JAK-IN-52096999-92-5JAKJanus kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *